Hsp90-targeting conjugates and formulations thereof
AssigneeTarveda Therapeutics, Inc.
InventorsBrian H. WHITE, Benoît MOREAU, Tyler CIPRIANI, Mark T. BILODEAU
Life of this patent
Estimating the term…
Loading patent…
AssigneeTarveda Therapeutics, Inc.
InventorsBrian H. WHITE, Benoît MOREAU, Tyler CIPRIANI, Mark T. BILODEAU
Estimating the term…
Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
A conjugate comprising an active agent coupled, via a linker, to an HSP90 targeting moiety, wherein the active agent is a PI3K inhibitor and wherein the PI3K inhibitor is selected from the group consisting of BGT-226 (NVP-BGT226), PF-05212384, PF-04691502, and fragments/derivatives/analogs thereof.
Dependencies are inferred from the claim text.